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ABSTRACT
Nucleotides in the free pool are more susceptible to
nonenzymatic methylation than those protected in
the DNA double helix. Methylated nucleotides like
O6-methyl-dGTP can be mutagenic and toxic if in-
corporated into DNA. Removal of methylated nu-
cleotides from the nucleotide pool may therefore be
important to maintain genome integrity. We show
that MutT homologue 1 (MTH1) efficiently catalyzes
the hydrolysis of O6-methyl-dGTP with a catalytic ef-
ficiency similar to that for 8-oxo-dGTP. O6-methyl-
dGTP activity is exclusive to MTH1 among human
NUDIX proteins and conserved through evolution but
not found in bacterial MutT. We present a high resolu-
tion crystal structure of human and zebrafish MTH1
in complex with O6-methyl-dGMP. By microinjecting
fertilized zebrafish eggs with O6-methyl-dGTP and
inhibiting MTH1 we demonstrate that survival is de-
pendent on active MTH1 in vivo. O6-methyl-dG levels
are higher in DNA extracted from zebrafish embryos
microinjected with O6-methyl-dGTP and inhibition of
O6-methylguanine-DNA methyl transferase (MGMT)
increases the toxicity of O6-methyl-dGTP demon-
strating that O6-methyl-dGTP is incorporated into
DNA. MTH1 deficiency sensitizes human cells to the
alkylating agent Temozolomide, a sensitization that
is more pronounced upon MGMT inhibition. These
results expand the cellular MTH1 function and sug-
gests MTH1 also is important for removal of methy-
lated nucleotides from the nucleotide pool.
INTRODUCTION
DNA can be methylated nonenzymatically by environmen-
tal methylating agents, chemotherapeutics such as Temo-
zolomide (1) and natural cellular methyl donors like S-
adenosylmethionine (SAM) (2). Free nucleotides are re-
ported to be∼190–13 000 times more susceptible to methy-
lation damage, depending on the site of methylation, com-
pared to when present in the DNA (3). This is likely due to
a higher accessibility of free nucleotides compared to when
present in the densely packed DNA. The order of suscep-
tibility for methylation of free nucleotides by N-methyl-N-
nitrosourea was found to be dependent on the site on the
base, with methylations at the N1 position of adenine being
the most common, followed by the N3 position of adenine.
The most susceptible position on guanine was the N7 po-
sition followed by the O6 position (3). If incorporated into
DNA these methylated nucleotides can produce mutations
and toxic DNA lesions. For example, N3-methyl-A blocks
replication, O6-methyl-G induces G:C to A:Tmutations (4)
and causes DNA strand breaks and replication fork col-
lapse (5) and N7-methyl-G gives rise to mutagenic apurinic
sites and blocks DNA replication (6–8).
The importance of removing methylations from DNA
to prevent mutations and DNA lesions is relected in the
presence of an array of DNA-glycosylases that remove
methylated bases from the DNA. N3-methyladenine, N7-
methylguanine and N3-methylguanine are removed from
DNA by alkyladenine-DNA glycosylase (9,10). AlkB ho-
mologue dioxygenases repair alkylated DNA containing
N1-methyladenine by oxidative demethylation (11–13). O6-
methyl-G adducts are removed from the DNA in a suicide
reaction where the methyl group is transferred to a cysteine
in the active site of O6-methylguanine-DNA methyltrans-
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ferase (MGMT) (14). Given the importance of preventing
unwanted methylations in the DNA for genome integrity
and the high susceptibility to methylation of the free nu-
cleotide pool we argued that removal of methylated dNTPs
from the free nucleotide pool also would be important. In
addition, the presence of O6-methyl-guanosine in RNA has
been shown to alter the idelity and the translation rate of
the ribosome (15). Hence, it would also be of importance
to remove O6-methyl-GTP from the NTP pool to decrease
cellular toxicity.
MutT homologue 1 (MTH1) belongs to theNUDIXpro-
tein family and is known to be responsible for removal
of oxidized purine nucleoside triphosphates from the nu-
cleotide pool (16). We set out to investigate if MTH1 also
can catalyze the hydrolysis of methylated nucleotides. We
here show that MTH1 constitutes another line of defense
against DNA methylations by eficiently catalyzing the hy-
drolysis of O6-methyl-dGTP. We reveal the importance of
MTH1 activity in cells exposed to O6-methyl-dGTP for
survival in vivo and demonstrate that the ability of MutT
homologues to hydrolyze O6-methyl-dGTP has been con-
served through evolution and is exclusive to MTH1 among
human NUDIX enzymes.
MATERIALS AND METHODS
Human MTH1 expression and puriication
MTH1 expression and puriication was performed as pre-
viously described (17). Briely, human MTH1 (hMTH1,
NUDT1) was expressed from pET28a(+) (Novagen), con-
taining MTH1 cDNA optimized for expression in Es-
cherichia coli (E. coli), in strain BL21 DE3 (Stratagene).
His tagged MTH1 was afinity puriied using HisTrap HP
(GE Healthcare). His tag was removed by thrombin diges-
tion (Novagen) and the MTH1 protein was further puriied
using anion exchange chromatography at pH 7.5 using a
MonoQ column (GE Healthcare). The identity and purity
of the protein was conirmed using SDS-PAGE gel analysis
and MALDI-TOF mass spectrometry (MS).
MTH1 activity determination
In order to investigate if MTH1 can hydrolyze methylated
dGTPs the activity of MTH1 was tested with the methy-
lated dGTPs that were available for purchasing, O6-methyl-
dGTP and N2-methyl-dGTP (TriLink Biotechnologies).
Activity of MTH1 (5 nM) was tested in MTH1 reaction
buffer (100 mM Tris acetate pH 7.5, 40 mM NaCl, 10 mM
Magnesium acetate, 1 mM DTT) with 50 M O6-methyl-
dGTP or N2-methyl-dGTP and for comparison with 50
M dGTP and 50 M 8-oxo-dGTP, at 22◦C using a reac-
tion time of 30 min. Formed PPi was converted to Pi by
using an excess of E. coli PPase (0.2 U/ml) (produced by
the Protein Science Facility at the Karolinska Institute) as
described (18) and Pi was detected by addition of malachite
green reagent followed by incubation with shaking for 15
min and measurement of the absorbance at 630 nm (19).
The amount of Pi present in the sample was determined
by converting A630 to [Pi] by using a Pi standard curve.
Activity differences between samples in quadruplicate were
tested for statistical signiicance usingmultiple comparisons
and one-way ANOVA (Alpha 0.05) using the GraphPad
Prism 6.0 software. Activity was also tested with 50 M
O6-methyl-GTP and GTP using 45 nM MTH1 in MTH1
reaction buffer with PPase (0.2 U/ml). Reactions were in-
cubated at 22◦C for 30 min and were run in quadruplicate.
Malachite green reagent was added to detect formed Pi as
described above. Statistic signiicance was tested using t-
test (two-tailedP-value) using theGraphPad Prism 6.0 soft-
ware.
The observed activity of MTH1 with O6-methyl-dGTP
prompted us to analyse the MTH1 catalyzed hydrolysis of
O6-methyl-dGTP more carefully. 5 mM O6-methyl-dGTP
was incubated with MTH1 (100 nM) at 22◦C in MTH1 re-
action buffer pH 8, and the reactionwas stopped at different
time points by protein denaturation through sample heat-
ing at 70◦C for 10 min followed by precipitation of dena-
tured protein by centrifugation at 17 000 g for 10 min at
4◦C. Supernatants were diluted 1:10 with distilled water and
samples were analysed using an Agilent 1100 HPLC system
equipped with a Hypercarb column (100 mm × 2.1 mm,
Thermo Fisher Scientiic), by using a basic pH method.
H2O (containing 10 mM NH4HCO3 pH 10) and Acetoni-
trile were used asmobile phases at a low rate of 0.5 ml/min.
The reaction mixture was separated using a gradient of 0–
40% Acetonitrile and a gradient time of 6.0 min and UV
light absorbance in the 180−305 nM range was used for de-
tection.
Kinetic parameters of MTH1 with O6-methyl-dGTP
and O6-methyl-GTP (TriLink Biotechnologies) were deter-
mined by assaying initial rates at substrate concentrations
ranging from 0 to 100 M for O6-methyl-dGTP and 0
to 400 M for O6-methyl-GTP in MTH1 reaction buffer
pH 7.5. Formed PPi was detected using the PPiLight inor-
ganic pyrophosphate assay (Lonza). A PPi standard curve
was used to convert assay signal to concentration PPi. The
kcat, KM and kcat/KM values were determined by itting the
Michaelis–Menten equation to initial rates monitored in
triplicates for each concentration using non-linear regres-
sion analysis in the GraphPad Prism Software.
Docking of N7-methyl-dGMP into MTH1 active site
The most susceptible position of guanine for methylation is
the N7 position giving rise to N7-methyl-dGTP in the free
nucleotide pool (20). To get an idea of how well N7-methyl-
dGTP its in the active site of MTH1 we performed molec-
ular modelling using Small-Molecule Drug Discovery Suite
2017-1 (Schro¨dinger, LLC, NewYork, NY, 2017). The crys-
tal structure of MTH1 in complex with 8-oxo-dGMP (pdb
3ZR0 (17) was prepared using the Protein PreparationWiz-
ard. Briely, the B chain was deleted and the A chain was
processed by automatically assigning bond orders, adding
hydrogens, creating zero-order bonds to metals, creating
possible disulide bridges, deleting waters beyond 5.0 A˚ of
het groups, and generating het states at pH 7.0. Protona-
tion and metal charge states were then generated for the
het groups and visually inspected, and the most likely states
based on H-bonding pattern and state penalty were se-
lected. Two sulfate groups were deleted at this point. The
hydrogen bonding network was initially optimized interac-
tively, locking Asp119 and Asp120 as neutral and charged,
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respectively, and then the remaining species were optimized
automatically, by sampling water orientations and opti-
mization of hydroxyls, Asn, Gln and His states using Pro-
tAssign. Subsequently all waters with <4 H-bonds to non-
waters were removed, and inally the structure was submit-
ted to a restrained minimization in the OPLS3 force ield,
until the heavy atom positions had converged to an RMSD
of 0.30 A˚. Glide docking grids were then generated by cen-
tering them onto bound 8-oxo-dGMP. N7-methyl-dGMP
was manually created from 8-oxo-dGMP, and low-energy
3D starting conformations of both ligands were then gener-
ated using LigPrep. N7-methyl-dGMP was then docked to
the active site of MTH1 using Glide XP, without any con-
straints.
Production and analysis of methylated dGTP and analysis of
MTH1 activity using HPLC
N7-methyl-dGTP could not be purchased presumably due
to a short half-life. We therefore produced N7-methyl-
dGTP and tested the ability of MTH1 to catalyze the hy-
drolysis of N7-methyl-dGTP. dGTP was methylated by in-
cubating 50 mM dGTP (Sigma-Aldrich) at 22◦C for 20 h
with 100 mMMMS diluted in DMSO, or the same volume
DMSO, resulting in a dGTP:MMS ratio of 1:2. Methylated
dGTP was also generated by incubating 10 mM dGTP at
22◦C for 20 hwith 300mMIodomethane diluted inDMSO-
d6:D2O ratio 3:1 for analysis using NMR. For assessment
of MTH1 activity, MMS treated dGTP and DMSO control
were diluted to 5 mM with MTH1 reaction buffer (0.1 M
Tris acetate pH 8.0, 40 mM NaCl, 10 mM Magnesium ac-
etate) followed by incubation with 500 nMMTH1 at 22◦C.
The hydrolysis reaction was stopped at different time points
by heat inactivation at 70◦C for 10min followed by centrifu-
gation at 17 000 g for 10 min at 4◦C. Reactionmixtures were
analysed using HPLC equipped with a Hypercarb column
andmolecularmasses were determined using LC–MS as de-
scribed below.
Analysis of nucleotide samples using HPLC–MS and NMR
NMR spectra of dGTP and N7-methyl-dGTP, prepared by
methylation of dGTP using MMS and Iodomethane, were
recorded on a Bruker DRX-400. Chemical shifts are ex-
pressed in parts per million (ppm) and referenced to the
residual solvent peak. Molecular masses were determined
using HPLC–MS utilizing an AgilentMSDmass spectrom-
eter connected to an Agilent 1100 HPLC system equipped
with an XTerra column (MSC18, 50 mm × 3.0 mm) and
by using a basic pH method utilizing H2O (containing 10
mM NH4HCO3 pH 10) and Acetonitrile as mobile phases.
The HPLCmethod used a low rate of 1 ml/min, a gradient
of 0–10% Acetonitrile and a gradient time of 3.0 min. For
detection absorbance in the 180−305 nM range was used.
Masses were determined using electrospray ionization MS.
Production of human NUDIX enzymes
Expression constructs of NUDT4 (DIPP2) and NUDT9
were constructed by amplifying cDNA that was synthe-
sized from HL60 cell RNA isolated in house, and was
subcloned into pET28a(+) (Novagen). Expression con-
structs of NUDT2, NUDT7, NUDT17 and NUDT18
were produced by subcloning of cDNA, purchased as
codon optimized for E. coli expression from GeneArt (Life
technologies), into pET28a(+) (Novagen). NUDT21 and
NUDT22 cDNAs were purchased from Source BioScience
and subcloned into pET28a(+). Correctness of expression
constructs sequences was veriied by sequencing. Expres-
sion constructs of NUDT3 (aa 8–172), NUDT5, the cat-
alytic subunit of NUDT6, NUDT10 (variant AAH50700),
NUDT11 (aa 13–164), NUDT12, NUDT14, NUDT15 and
NUDT16 (variant AAH31215) all in pNIC28 were kind
gifts from SGC Stockholm. All NUDIX proteins were
expressed and puriied as N-terminally His-tagged pro-
teins apart from NUDT10 and NUDT11 that were C-
terminally tagged. Expression strain wasE. coliBL21(DE3)
R3 pRARE2 and expression was performed at 18◦C. Pro-
teins were puriied by the Protein Science Facility (PSF)
at Karolinska Institute, Stockholm. The N-terminally His-
tagged NUDIX proteins were puriied using HisTrap HP
(GEHealthcare) followed by gel iltration onHiLoad 16/60
Superdex 75 (GE Healthcare). NUDT2 was produced in
BL21 DE3 (Life Technologies) by overnight expression at
18◦C and was puriied using HisTrap HP followed by ion
exchange chromatography onHPmonoQ (GEHealthcare).
The NUDIX proteins were concentrated and stored at –
80◦C in storage buffer (20 mM HEPES pH 7.5, 300 mM
NaCl, 10%Glycerol and 0.5 mMTCEP). The purity of pro-
tein preparations was examined using SDS-PAGE followed
by Commassie staining and the correct mass of the puriied
proteins was veriied using MS.
O6-methyl-dGTP activity screening of human NUDIX hy-
drolases
The activity of human NUDIX proteins with 50 M O6-
methyl-dGTP was assessed in reaction buffer (100 mM Tris
acetate pH 7.5, 40 mMNaCl, 10 mMMagnesium acetate, 1
mM DTT) at 22◦C. Reactions were performed in presence
of 0, 5 or 200 nMNUDIXprotein diluted in reaction buffer,
containing an excess of E. coli PPase (0.2 U/ml) or with-
out coupled enzyme. After 30 min incubation with shaking
malachite green reagent was added to detect the formed in-
organic phosphate (19). After 15 min incubation with shak-
ing 10 l 0.4 M Sodium citrate was added to the 40 l re-
action mixture to stop the development. Absorbance was
measured at 630 nm using an EnVision plate reader (Perkin
Elmer).
Activity assessment of MTH1, NUDT17 and NUDT18 with
methylated nucleoside triphosphates
To further investigate the capacity of MTH1 to catalyze the
hydrolysis of methylated nucleoside triphosphates we tested
the activity of 5 nM MTH1 with a panel of methylated
(d)NTPs and for comparison the corresponding canoni-
cal (d)NTP, when available, at 50 M. The nucleotides in-
cluded in the substrate screen were: dATP (Sigma Aldrich,
DNTP-100), ATP (Sigma Aldrich, A26209), N1-methyl-
ATP (Jena Biosciences NU-1027), N6-methyl-ATP (Jena
Biosciences, NU-1101), UTP (Sigma Aldrich, U1006), 5-
methyl-UTP (Jena Biosciences, NU-880), dCTP (Sigma
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Aldrich, DNTP-100), 5-methyl-dCTP (TriLink Biotech-
nologies, N-2026), 5-methyl-CTP (Jena Biosciences, NU-
1138), GTP (SigmaAldrich, G3776), 7-methyl-GTP (Sigma
Aldrich, M6133), O6-methyl-GTP (TriLink Biotechnolo-
gies, N-1031), dGTP (Sigma Aldrich, 27-1870-04) and for
comparison O6-methyl-dGTP (TriLink Biotechnologies,
N-2027). The reaction buffer was 100 mM Tris acetate pH
8.0, 40 mMNaCl and 10 mMMagnesium acetate and con-
tained 0.2 U/ml PPase. Formed Pi was after 30 min incu-
bation with shaking at 22◦C detected using the malachite
green assay by measuring the absorbance at 630 nm us-
ing a Hidex plate reader. Signal from PPase only controls
were subtracted from sample signals. Since NUDT17 and
NUDT18 showed some activity with O6-methyl-dGTP we
decided to test the activity with these enzymes with the
above mentioned panel of nucleotides using the same as-
say conditions as for MTH1 but using 200 nM NUDT17
and NUDT18. Two independent experiments with samples
in triplicate were performed.
Production of MTH1 proteins from various species
cDNAs for clMTH1 (dog), ssMTH1 (pig), mmMTH1
(mouse), rnMTH1 (rat) and atNUDT1 (Arabidopsis
thaliana plant) were purchased as codon optimized for E.
coli expression from GeneArt (Thermo Fisher Scientiic)
or Euroins and subcloned into pET28a(+) (Novagen).
The zfMTH1 (zebraish) expression construct has been
described previously (21). Proteins were expressed in E. coli
BL21 (DE3) R3 pRARE2 or BL21 (DE3) T1R pRARE2
(mmNUDT1) in Terriic Broth (TB) media at 18◦C for 16
h after induction by 0.5 mM IPTG. Proteins were puriied
from the bacterial lysate using HisTrap HP followed by gel
iltration on HiLoad 16/60 Superdex 75. E. coliMutT was
produced as described previously (22). Puriied proteins
were analysed for purity using SDS-PAGE and analysed by
MS to verify the correct protein mass. Proteins were stored
as aliquots at –80◦C in 20 mM HEPES buffer pH 7.5, 500
mM NaCl, 10% Glycerol and 0.5 mM TCEP.
Determination of activity of MTH1 from different species
with O6-methyl-dGTP and 8-oxo-dGTP
Activity of MTH1 from different species was tested by in-
cubating 1.5 nM of MTH1 from respective species with 75
M8-oxo-dGTP or 75 MO6-methyl-dGTP inMTH1 re-
action buffer (100mMTris acetate pH 8.0, 40mMNaCl, 10
mM Magnesium acetate, 1 mM DTT) for 15 min. Formed
PPi was detected using PPiLight Inorganic Pyrophosphate
Assay kit from Lonza bymeasuring luminescence with time
using a Hidex Sense plate reader.
Production of zfMTH1 for crystallization
The zfMTH1 protein for crystallographic studies was ex-
pressed in E. coli BL21 (DE3; Novagen) by induction with
0.5 mM IPTG at an OD600 of 1.0 in Terriic Broth media
and further growth at 18◦C overnight. Bacteria were har-
vested by centrifugation and lysate was prepared by adding
Lysis buffer (100 mMHEPES, pH 8.0, 500 mMNaCl, 10%
(v/v) Glycerol, 0.5 mM TCEP) containing lysozyme, 5 mM
MgSO4, DNAse, and protease inhibitor cocktail (Roche)
followed by high-pressure homogenization and centrifuga-
tion. His-tagged zfMTH1 was puriied on gravity low col-
umn (Econo-Pac Chromatography column, Bio-Rad) after
incubation with Ni-NTA (1.0 ml/50 ml cleared lysate) and
10 mM Imidazole, washed with Buffer A (20 mM HEPES
buffer pH 7.5, 500 mM NaCl, 10% Glycerol, and 0.5 mM
TCEP) fortiied with 10 mM Imidazole followed by elution
of the protein with Buffer A fortiied with 500 mM Imida-
zole. MTH1 containing fractions were pooled and loaded
on a PD-10 desalting column (GEHealthcare) equilibrated
with Buffer B (20 mMHEPES pH 7.5, 300 mMNaCl, 10%
Glycerol, and 0.5 mM TCEP). Eluted protein was cleaved
by Thrombin (GEHealthcare) over night at 4◦C, then puri-
ied using Ni-NTA with Buffer B fortiied with 10 mM Imi-
dazole. Fractions containing zfMTH1 were pooled, loaded
on a Superdex 75 16/60 column (GE Healthcare), and pu-
riied using Buffer B. Fractions containing zfMTH1 were
pooled and purity was analysed on SDS-PAGE. Protein
was concentrated using Vivaspin 20 (Sartorious Stedim), 10
kDaMWCO. Concentration was determined by measuring
A280 and using a calculated extinction coeficient of 24 980
M−1 cm−1.
Crystallization and structure determination
3 mM O6-methyl-dGTP and 2 mM TCEP was added to
the human MTH1 protein. Sitting drop vapor diffusion
experiments were performed at 20◦C, and human MTH1
(16.9 mg/ml in 20 mM Tris–HCl pH 7.4, 150 mM NaCl
and 5% (v/v) Glycerol) was mixed with reservoir solution
(26% (w/v) PEG6000, 100 mMSodiumAcetate pH 3.7 and
200 mM LiSO4) in a 1:1 ratio. Diffraction quality crystals
appeared after approximately 3 days, and were lash frozen
in liquid nitrogen. Data collection was performed at 100 K
at beamline 14.1 at BESSY, Germany. 2.5 mM O6-methyl-
dGTP and 6 mM MgCl2 were added to the zfMTH1 pro-
tein. Crystals were grown using the sitting drop vapor dif-
fusion technique. ZfMTH1 (45.17 mg/ml) was mixed with
reservoir solution (200 mM CaCl2, 100 mM MES pH 6.0,
20% (w/v) PEG6000) in a 1:3 ratio. Diffraction quality crys-
tals appeared after about 3 days at 20◦C. Crystals were cryo-
protected by soaking in 50% mother liquor supplemented
with 42.5% Glycerol, and were subsequently lash frozen in
liquid nitrogen. Data collection was performed at 100 K at
beamline I04-1 at Diamond, United Kingdom.
Data reduction and processing was carried out using
XDS (23) and programs from the CCP4 suite (24). Rel-
evant statistics can be found in Supplementary Table S1.
The structures were solved via molecular replacement using
Phaser (25), using the previously solved apo MTH1 struc-
ture (pdb 3ZR1) as search model for the human MTH1
structure and the previously solved zfMTH1 structure (pdb
5HZX) as search model for the zfMTH1 structure. A few
cycles of reinement in Refmac5 (24,26), interspersed with
manual building in Coot (27,28), were needed to complete
the models. Water molecules were automatically placed in
the maps, using a FO – FC Fourier difference map cutoff
of 3, and were subsequently validated to ensure correct
positioning. All structure igures were prepared using Py-
MOL (Schro¨dinger). Ramachandran statistics were gener-
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ated using MolProbity (29,30). The structures have been
deposited in the protein data bank with accession codes
5OTM (hMTH1) and 5OTN (zfMTH1).
Structure comparisons
RMSD comparisons between structures for C-atoms were
obtained using the protein structure comparison service
PDBeFold at European Bioinformatics Institute (http://
www.ebi.ac.uk/msd-srv/ssm), authored by Krissinel and
Henrick (31).
Determination of activity with O6-methyl-dGTP and dGTP
of human and zebraish MTH1
To assess the relative activity of zfMTH1 with O6-methyl-
dGTP versus dGTP and to compare the activity of zfMTH1
with the activity of human MTH1, 5 nM of the respective
enzymes were incubated with 100 MdGTP or O6-methyl-
dGTP in MTH1 reaction buffer (100 mM Tris acetate pH
8.0, 40 mMNaCl, 10 mMMagnesium acetate, 1 mMDTT)
for 20 min. Formed PPi was converted to Pi by using an ex-
cess of E. coli PPase followed by detection of Pi using mala-
chite green reagent and absorbance measurement at 630
nm. A Pi standard curve was used to convert absorbance
to formed Pi.
Inhibition of zfMTH1
TH588 and TH1579 were previously identiied as potent in-
hibitors to human MTH1 and prepared as previously de-
scribed (22,32). To determine the potency of these com-
pounds towards zfMTH1, TH588 and TH1579 were seri-
ally diluted in 1:3 dilution series resulting in 12 inal in-
hibitor concentrations ranging from 10 M to 0.06 nM.
Each inhibitor concentration was run in duplicate. Reac-
tion buffer was 100 mM Tris acetate pH 8.0, 40 mM NaCl,
10 mMMagnesium acetate, 1 mMDTT and 0.005% Tween
20. Final concentration of zebraish MTH1 (zfMTH1) and
dGTP were 5 nM and 100 M, respectively. E. coli PPase
was added to a inal concentration of 0.2 U/ml. Control
reactions, lacking inhibitor or enzyme, were included on
the assay plate. The reactions were incubated with shak-
ing at 22◦C for 20 min followed by addition of malachite
green assay reagent (19) and incubation with shaking for 15
min at 22◦C. Absorbance was measured at 630 nm using a
Hidex Sense plate reader. IC50-values were determined by
itting the equation: log[inhibitor] versus response – vari-
able slope to the inhibition data using nonlinear regression
in the GraphPad Prism Software.
Zebraish survival experiment with O6-methyl-dGTP and
MTH1 inhibitors
Zebraish (TL strain) were raised and staged according to
standard protocols. Fertilized eggs were injected with ∼2
nl of 0.15 mM O6-methyl-dGTP (TriLink Biotechnology)
in injection buffer (9 M spermine, 0.21 M spermidine,
0.3% phenol red), distributed to six-well plates with 3 ml
E3medium (5mMNaCl, 0.17mMKCl, 0.33mMCaCl2×2
H2O, 0.33 mMMgSO4) and exposed to 1.5 MTH588, 1.5
M TH1579 or DMSO added to the water within 15 min
after injection. Twenty four hours after injection, embryo
viability was analysed (severely malformed individuals or
embryos lacking heart beat were counted as dead).
Survival and DNA analysis of O6-methyl-dGTP, MTH1 and
MGMT inhibitor treated zebraish
An enhancement of O6-methyl-dGTP toxicity by MGMT
inhibition would suggest that O6-methyl-dGTP toxicity is
exerted through incorporation into DNA. To test this O6-
methyl-dGTP was injected into fertilized zebraish eggs as
described above, MGMT inhibitor Lomeguatrib (1 M)
(selleckchem.com), TH588 (1.5 M) or DMSOwere added
to the water, either alone or in combination (40–60 eggs
in each group). Viability of zebraish embryos was assessed
after 24 h. In addition, DNA from the different treatment
groups was isolated using the DNeasy Blood & Tissue Kit
(Qiagen) and analysed for presence of O6-methyl-dG and
N7-methyl-dGusingLC–MS/MS. Prior to nucleoside anal-
ysis, RNA in the DNA isolates was degraded by incubat-
ing samples with 10 g RNase (Sigma-Aldrich) in 10 mM
Ammonium bicarbonate pH 7.0, 1 mM MgCl2, and 0.1
mM Deferoxamine mesylate (DFO; Santa Cruz Biotech-
nologies) at 37◦C for 30 min. Free nucleosides and nu-
cleotides were then removed from samples by centrifugation
through 30 kDa molecular weight cut-off columns (Merck)
and re-dissolved in UHPLC-grade water. After RNAse pre-
treatment, 15 g DNA were hydrolyzed in 50 l buffer
(10 mM Ammonium acetate pH 5.5, 1 mM MgCl2, and
0.1 mM ZnCl2) containing 0.8 U nuclease P1 from P. cit-
rinum (Sigma-Aldrich), 80UBenzonase® nuclease (Sigma-
Aldrich), and 0.2 U Alkaline phosphatase from E. coli
(Sigma-Aldrich) at 37◦C for 1 h. The reactions were stopped
by cooling on ice, and proteins were precipitated by adding
three volumes ice-cold Acetonitrile and centrifuging at 16
000 g for 30 min. Supernatants were then lyophilized at –
80◦C to dryness. Finally, the samples were re-dissolved in
30 l water for LC/MS/MS analysis, of which 5 l were
diluted 5000-fold to measure the four canonical nucleosides
and 20 l were used to measure modiied nucleosides. Mod-
iied nucleosides were analysed with an Agilent 6495 triple
quadrupole LC/MS/MS system with an Agilent Eclipse-
PlusC18 RRHD column (2.1 × 150 mm, 1.8 m parti-
cle size). The mobile phases were (A) UHPLC-grade wa-
ter and (B) UHPLC-grade methanol, both containing 0.1%
UHPLC-grade formic acid. The HPLCmethod used a low
rate of 300 l/min with 5% B to 2.5 min, ramp to 13% B at
3 min, ramp to 17.16% B at 5.5 min, hold at 35% B from 5.5
to 7 min, ramp to 5% at 8 min, and equilibration with 5% B
from 7 to 11.5 min. Unmodiied nucleosides were measured
on an API5000 triple quadrupole mass spectrometer (Ap-
plied Biosystems) with an Acentis® Express C18 column
(0.5 × 150 mm, 2.7 m particle size). The HPLC method
used a low rate of 150 l/min with an isocratic low of 25%
B for 3 min with the column heated to 40◦C. The mass tran-
sitions used were 282.1 → 166.1, 252.1 → 136, 228.1 →
111.9, 268.1→ 152, and 243.1→ 127 m/z for met-dG, dA,
dC, dG, and dT, respectively.
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Activity test of zfMTH1 with Ca2+ and Mg2+
In order to test if Mg2+ can be replaced by Ca2+ with re-
tained zfMTH1 activity the activity of zfMTH1 with 100
M dGTP was tested at 0, 0.125, 0.25, 0.5 and 1 nM
zfMTH1 in reaction buffer (100 mMTris acetate pH 8.0, 40
mMNaCl, 1 mMDTT) supplemented with 10 mMMgCl2
or CaCl2. After 20 min, the reaction was stopped by heat
inactivation at 90◦C for 10 min. After cooling to room tem-
perature formed PPi was detected using PPiLight inorganic
pyrophosphate assay (Lonza) according to the manufactur-
ers’ recommendations.
Analysis of role of MTH1 for apoptosis and viability in cells
treated with Temozolomide
To analyse the effect of MTH1 on the sensitivity of cells
to the alkylating agent Temozolomide, which exerts its
toxicity primarily through methylation of O6-guanine, we
made use of two glioblastoma cell lines, U251 and U251-
MTH1 in which the MTH1 gene had been deleted using
CRISPR/Cas9. These two cell lines were kind gifts from
Dr Massimo Squatrito. MTH1 knockout was veriied us-
ing western blotting using rabbit anti-MTH1 (Novus Bio-
logicals). Cells were seeded in MEMmedium (Gibco), 10%
FBS (Gibco), 50g/ml Pen/Strep (Gibco), 1%MEMNon-
Essential Amino Acids Solution (100×) (Gibco) and 1 mM
Sodium pyruvate (Gibco) and treated with DMSO, Temo-
zolomide (15M, Sigma-Aldrich) or Lomeguatrib (20M,
selleckchem.com) or with both Temozolomide (15M) and
Lomeguatrib (20 M). Caspase 3/7 activity was monitored
as a measure of early apoptosis after 48 h of treatment (800
cells were seeded in each well of a 384-well plate) at eight
different Temozolomide and Lomeguatrib concentrations
ranging from 0 to 100M, using the Caspase-Glo 3/7 assay
(Promega) according to the manufacturer’s recommenda-
tions. For assessment of cell viability, 400 cells were seeded
in each well of a 384-well plate and Temozolomide and
Lomeguatrib were added as described for the apoptosis as-
say. Cell viability was measured after 96 h using Resazurin
as previously described (22).
RESULTS
MTH1 eficiently catalyzes O6-methyl-dGTP hydrolysis
As methylation damage preferentially affects the dNTP
pool (3) and since removal of methylated dNTPs may very
well be important for cell survival we tested the ability of
MTH1 to sanitize the damaged dNTP pool by catalysing
the hydrolysis of methylated nucleotides. Comparison of ac-
tivities ofMTH1 with O6-methyl-dGTP, N2-methyl-dGTP,
dGTP and the previously best known MTH1 substrate 8-
oxo-dGTP showed that O6-methyl-dGTP was hydrolyzed
at a level similar to that of 8-oxo-dGTP (Figure 1A). How-
ever, the activity of MTH1 with N2-methyl-dGTP was only
slightly higher than with dGTP. We also tested the activ-
ity of MTH1 with the corresponding ribonucleotide O6-
methyl-GTP and compared it to the activity withGTP (Fig-
ure 1B) and found the activity of MTH1 with O6-methyl-
GTP to be approximately 4-fold higher than for GTP. How-
ever, the activity with O6-methyl-GTP under the used con-
ditions was approximately 70-fold lower compared to with
O6-methyl-dGTP. The MTH1 catalyzed hydrolysis of O6-
methyl-dGTP was also analysed using HPLC and LC–MS
showing that the product formed is O6-methyl-dGMP as
expected (Supplementary Figure S1A). For more detailed
analysis of the activity of MTH1 with O6-methyl-dGTP
and O6-methyl-GTP saturation curves were produced (Fig-
ure 1C and D) and kinetic parameters for MTH1 with O6-
methyl-dGTP and O6-methyl-GTP were determined (Table
1). Comparison of kinetic parameters for MTH1 with O6-
methyl-dGTP with those determined previously for 8-oxo-
dGTP under the same conditions shows that kcat and Km
values are similar resulting in kcat/Km-values in the same
range for these two substrates (Table 1).
Activity with O6-methyl-dGTP is exclusive toMTH1 among
human NUDIX proteins
In order to examine if MTH1 is the only human NUDIX
protein that can catalyze the hydrolysis of O6-methyl-dGTP
we produced and tested 17 of the human NUDIX proteins
for activity with O6-methyl-dGTP at a low (5 nM) and a
high concentration (200 nM) to allow detection also of low
activities as previously described with other substrates (33).
The reactions were coupled to E. coli PPase producing Pi
from formed PPi (Figure 2A) or performed without cou-
pled enzyme showing direct formation of Pi (Figure 2B).
At 5 nM enzyme only MTH1 hydrolyzed O6-methyl-dGTP
to any detectable level giving rise to O6-methyl-dGMP and
PPi. Some hydrolysis of O6-methyl-dGTP was also ob-
served by NUDT17 and NUDT18 but only when using
200 nM enzyme in the assay (Figure 2A). Low activity was
also observed using 200 nM NUDT2, NUDT9, NUDT10,
NUDT12 and NUDT15. 200 nM NUDT18 showed weak
hydrolysis of O6-methyl-dGTP to O6-methyl-dGDP and
Pi (Figure 2B). Slight production of Pi was also observed
for 200 nM NUDT2, NUDT9, NUDT10, NUDT12 and
NUDT17 (Figure 2B). To conclude, this experiment clearly
shows that MTH1 by far is the best catalyst of O6-methyl-
dGTP hydrolysis among human NUDIX proteins.
Activity screen of MTH1, NUDT17 and NUDT18 with a
panel of methylated nucleotides
As MTH1 showed considerable activity with O6-methyl-
dGTP we sought to investigate if we could identify other
methylated (d)NTP species as substrates for MTH1. Anal-
ysis of the activity of MTH1 with a panel of methylated
(d)NTPs and their canonical counterparts did not iden-
tify any of the tested methylated nucleotides as good sub-
strates of MTH1. However, MTH1 did catalyze the hydrol-
ysis of 5-methyl-dCTP more eficiently than dCTP (Fig-
ure 3A) although not to the same extent as hydrolysis of
dGTP or O6-methyl-dGTP. Since NUDT17 and NUDT18
were found to display some activity with O6-methyl-dGTP
(Figure 2A) we also screened these enzymes for activity
with the same panel of methylated (d)NTPs, including O6-
methyl-GTP, and nonmethylated nucleotides (Figure 3B).
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Figure 1. MTH1 is an eficient catalyst of O6-methyl-dGTP hydrolysis. (A) Activity assessment of MTH1 with O6-methyl-dGTP and N2-methyl-dGTP
in comparison to dGTP and 8-oxo-dGTP. Activity of 5 nM MTH1 was tested with 50 M substrate in MTH1 reaction buffer with PPase (0.2 U/ml).
Formed Pi was detected using the malachite green reagent. Activity differences between samples in quadruplicate were found to be statistically signiicant
by multiple comparisons using One way Anova in the GraphPad Prism 6.0 software. (B) Activity ofMTH1 (45 nM) with 50 MO6-methyl-GTP and GTP
was measured as in (A) with samples in quadruplicate. Statistic signiicance was analysed using Paired Two-tailed T-test using the GraphPad Prism 6.0
software. (C) Saturation curve for MTH1 with O6-methyl-dGTP were produced by determining initial rates using 1.25 nMMTH1 and O6-methyl-dGTP
ranging in concentration between 0 and 40 M. (D) Saturation curve for MTH1 with O6-methyl-GTP. 50 nMMTH1 and O6-methyl-GTP ranging from
0 to 400 M were used. Shown are representative saturation curves out of two independent experiments for each substrate with data points recorded in
duplicate. P ≤ 0.05 are considered to be statistically signiicant and are indicated by *, P ≤ 0.01 are indicated by **, P ≤ 0.001 are indicated by *** and P
≤ 0.0001 are indicated by ****.
Table 1. Kinetic parameters of MTH1
Km (M) kcat (s
−1) kcat/Km (M
−1s−1)
O6-methyl-dGTP 15.6 ± 0.2 8.2 ± 0.9 515 000 ± 80 000 n = 2
O6-methyl-GTP 236 ± 44 0.3 ± 0.1 1160 ± 580 n = 2
8-oxo-dGTP* 13.2 3.3 246 200
10.2 8.6 840 200
*Data from (17), and (41), n denotes number of experiments. kcat, KM and kcat/KM values were determined by itting the Michaelis–Menten equation to
initial rates using non-linear regression analysis utilizing the GraphPad Prism Software. Values shown are average and standard deviations.
Neither NUDT17 nor NUDT18 show any notable activ-
ity with any of the tested nucleotides. However, NUDT17
seems to, similar to MTH1, display a preference for methy-
lated nucleotides and catalyzes the hydrolysis of O6-methyl-
dGTP and 5-methyl-UTPmore eficiently than their canon-
ical counterparts although the displayed activity is very low
(Figure 3B). Such preference formethylated nucleotides was
not observed for NUDT18.
N7-methyl-dGTP is not a substrate for MTH1
A second major methylation product of dGTP in addition
to O6-methyl-dGTP is N7-methyl-dGTP (20). We therefore
decided to investigate if N7-methyl-dGTP could act a sub-
strate for MTH1. We made use of in silico docking of N7-
methyl-dGMP into the active site of the crystal structure of
MTH1 (pdb 3ZR0) (Supplementary Figure S2) to get an
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Figure 2. Hydrolysis activity of MTH1 with O6-methyl-dGTP is exclusive among NUDIX hydrolases. Activity screen of human NUDIX proteins with
50 MO6-methyl-dGTP was tested using 0, 5, or 200 nM NUDIX enzyme in presence of an excess of PPase (A) monitoring formation of Pi and PPi, or
without coupled enzyme (B) detecting formation of Pi. Pi was detected using malachite green reagent and measurement of absorbance at 630 nm. Data
points were recorded in triplicate. Statistically signiicant differences in activity compared to the mock control was assessed using multiple comparison and
two-way ANOVA in GraphPad Prism 6.0. P ≤ 0.05 are considered to be statistically signiicant and are indicated by *, P ≤ 0.01 are indicated by **, P ≤
0.001 are indicated by *** and P ≤ 0.0001 are indicated by ****.
idea of how well N7-methyl-dGTP its in the active site of
MTH1. The in silico docking produced a low docking score
(Glide XP score -14.2 kcal/mol) indicating stronger bind-
ing ofN7-methyl-dGMP toMTH1 in comparison to 8-oxo-
dGMP (–11.7 kcal/mol). This suggests that N7-methyl-
dGTP could act as a substrate forMTH1 andMTH1might
protect against the formation of mutagenic apurinic (AP)
sites and DNA replication blocks caused by the presence
of N7-methyl-dG in the DNA (34) (6). The low docking
score is likely to be caused by the positive charge on N7
produced through N7-methylation allowing pi-cation inter-
actions with the aryl rings of W117 and F72 (35).
Encouraged by the result of the docking experiment we
set out to produce N7-methyl-dGTP, to be able to test it as
an MTH1 substrate, since it is not available for purchasing.
Methylations on nucleotides inDNAbyMMSmostly result
in N7-methylguanine (83%) (36) and only produce minor
amounts of O6-methylguanine (0.3% of dN methylations).
Based on this information and the fact that N7-methyl-
dGTP has been described to be the major product formed
after MMS or iodomethane treatment of dGTP (37,38), we
successfully generated N7-methyl-dGTP using this route.
The formation of N7-methylated dGTP from iodomethane
methylation of dGTP was veriied by NMR disclosing the
presence of a large H8-proton shift arising when the methy-
lation occurs at the N7 position (39,40) (Supplementary
Figure S3A and B). By combining HPLC, NMR and LC–
MS analysis we could conclude that N7-methyl-dGTP in-
deed is the major product formed upon MMS treatment
of dGTP. Prolonged incubation with excess of methylating
reagent resulted in increased formation of a di-methylated
product (presumably dGTP with methylations on both N3
andN7) with an elution time of approximately 4.8 min. Ad-
dition of MTH1 to the N7-methyl-dGTP preparation (pro-
duced by MMS treatment of dGTP) showed no observable
hydrolysis of N7-methyl-dGTP as analysed using HPLC
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Figure 3. Activity of MTH1, NUDT17 and NUDT18 with methylated
and nonmethylated nucleotide. (A) MTH1 (5 nM) and (B) NUDT17 (200
nM) and NUDT18 (200 nM) were screened for activity with a panel of
methylated and nonmethylated deoxyribonucleotides and ribonucleotides
by incubation with 50 Mnucleotide at 22◦C inMTH1 reaction buffer for
30 min. Formed Pi was detected using the Malachite green assay. Graphs
show average and SEM of [Pi] (M) per min per enzyme concentration
([Etot]) (M) from two independent experiments with data points in trip-
licate. Statistically signiicant differences between activity with nonmethy-
lated andmethylated nucleotides were determined using two-wayANOVA.
even after allowing the reaction to proceed for 4 h with an
excess of MTH1. Instead, nonmethylated dGTP in the re-
action mixture was hydrolyzed to dGMP under the condi-
tions used (Supplementary Figure S1B). The discrepancy
between the results of the in silico docking suggesting N7-
methyl-dGTP would be a possible MTH1 substrate based
on a good it and experimental data showing it is not em-
phasizes the importance of performing biochemical exper-
iments to support the results of in silico experiments. Alto-
gether, the results strongly suggests that N7-methyl-dGTP
is not a substrate of MTH1.
Activity ofMTH1withO6-methyl-dGTP has been conserved
through evolution
To ind out if the high activity of MTH1 with O6-methyl-
dGTP is found also in other species and has been conserved
through evolution we produced MTH1 from mouse, rat,
pig, dog, zebraish, the plant Arabidopsis thaliana and E.
coli MutT and tested the activity with O6-methyl-dGTP
and with 8-oxo-dGTP in parallel. Interestingly, MTH1 ho-
mologues from all tested species but E. coli were found to
catalyze the hydrolysis of O6-methyl-dGTP (Figure 4A).
Comparison of activities towards O6-methyl-dGTP and 8-
oxo-dGTP show that the activities are similar or even higher
towards O6-methyl-dGTP for some of the tested species ho-
mologues under the conditions used (Figure 4B). The ability
of all testedMTH1 proteins to hydrolyze O6-methyl-dGTP,
apart from MutT, suggests that this activity has been con-
served through evolution but has arisen after the bacterial,
archaeal and eukaryotic branches were separated from each
other in the phylogenetic tree of evolution.
Crystal structures of human and zebraishMTH1 with bound
O6-methyl-dGMP
In order to study the binding mode of O6-methyl-dGTP
and explain the high activity of MTH1 with O6-methyl-
dGTP co-crystals of both human and zebraish MTH1
with O6-methyl-dGTP were produced. The structure of hu-
man MTH1 with O6-methyl-dGMP, the hydrolysis prod-
uct, was solved at a resolution of 1.80 A˚, while the struc-
ture of zfMTH1 with O6-methyl-dGMP was solved at 0.99
A˚ resolution (see Supplementary Table S1 for details). The
binding and electron density for O6-methyl-dGMP in hu-
man MTH1 and zfMTH1 is shown in Figure 5A and B,
respectively. Within 6 A˚ of the methylated position, there
are a large number of hydrophobic residues, namely F27,
F72, F74, M81, W117, P118 (human) or A118 (zebraish)
and F139. When comparing the structure of humanMTH1
with O6-methyl-dGMP bound with the previously solved
structure of humanMTH1 with 8-oxo-dGMP bound, there
is a 1.1 A˚ shift in the position of the guanine base (see
Figure 5C), which brings the methylated part of the gua-
nine closer to the hydrophobic pocket. The overall struc-
tures of human MTH1 with O6-methyl-dGMP bound and
with 8-oxo-dGMP bound (pdb 3ZR0) are virtually iden-
tical. The RMSD value for backbone C-atoms compar-
ing the two structures, using PDBeFOLD (31) is as low as
0.20 A˚ showing that the protein backbone does not change
when having these two different ligands in the active site.
The zfMTH1 structure with O6-methyl-dGMP bound has
an RMSD for C-atoms of 0.60 A˚ and 0.74 A˚ when com-
pared to humanMTH1 with O6-methyl-dGMP bound and
human MTH1 with 8-oxo-dGMP bound (pdb 3ZR0), re-
spectively. When compared to the previously solved struc-
ture of zfMTH1 with inhibitor TH588 bound (pdb 5HZX)
the RMSD for zfMTH1 with O6-methyl-dGMP is 0.65 A˚.
The methylated base O6-methyl-dGMP binds highly sim-
ilar to both human MTH1 and zfMTH1 as seen in Sup-
plementary Figure S4B. The crystallization condition for
zfMTH1 included calcium ions and three calcium ions are
found in the structure close to O6-methyl-dGMP and the
NUDIX-box motif. The binding interface makes up a crys-
tal contact, with D62 and D92 from a second monomer in
the crystal interacting with the calcium ions (see Supple-
mentary Figure S7 for detailed binding). Magnesium ions
were found in the active site when solving the structure of
human NUDT15 (41). When comparing the binding of cal-
cium to zfMTH1 with the binding of magnesium to human
NUDT15 (MTH2, pdb 5BON) in Supplementary Figure
S8, two positions overlap but the third calcium ion is not
binding anywhere similar to the two remaining magnesium
ions to NUDT15. Since zfMTH1 was crystallized in pres-
ence of high concentrations of Ca2+ it is likely that the pres-
ence of Ca2+ instead of Mg2+ in the crystal structure is due
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Figure 4. Activity of MTH1 with O6-methyl-dGTP has been conserved through evolution. (A) Comparison of activities of MTH1 (NUDT1) (1.5 nM)
from different species with 75 M8-oxo-dGTP and 75 MO6-methyl-dGTP (hsNUDT1, human NUDT1; mmNUDT1, mouse NUDT1; rnNUDT1, rat
NUDT1; ssNUDT1, pig NUDT1; clNUDT1, dogNUDT1; atNUDX1, Arabidopsis thalianaNUDT1; zfNUDT1, zebraishMTH1;MutT,E. coliMutT).
Reaction was performed inMTH1 reaction buffer and reaction time was 15 min. Formed PPi was detected using PPiLight Inorganic Pyrophosphate Assay
kit from Lonza. Data points were recorded in triplicate. (B) Ratio between activities with O6-methyl-dGTP and 8-oxo-dGTP for MTH1 from different
species.
to the used crystallization conditions. However, to exclude
that Ca2+ can replaceMg2+ in the active site in the active en-
zyme, activity with dGTPwas tested in presence of either 10
mMCa2+ or 10mMMg2+. No activity could be observed in
presence of Ca2+ (Supplementary Figure S9). To conclude,
O6-methyl-dGMP its very well into the active site of both
human and zebraish MTH1, thus explaining the high ac-
tivity of MTH1 towards O6-methyl-dGTP.
Active MTH1 is needed for survival of zebraish embryos ex-
posed to O6-methyl-dGTP
After showing that MTH1 is an eficient catalyst of O6-
methyl-dGTP hydrolysis we decided to investigate the rel-
evance of this MTH1 activity by studying the effect of in-
activatingMTH1 when exposing to O6-methyl-dGTP in an
in vivo system. Delivery of nucleotide triphosphates into in-
tact cells is technically challenging due to their hydrophilic
properties. The zebraish embryo however provides a unique
in vivo model system to study nucleotide triphosphates as
those can be microinjected into fertilized eggs from where
they distribute equally and ubiquitously throughout the
growing embryo. We have previously shown that zebraish
is an excellent in vivo model to study the biology of MTH1
(21). The fact that zfMTH1 also displays activity with O6-
methyl-dGTP (Figure 4A) prompted us to test the activ-
ity of zfMTH1 and human MTH1 with O6-methyl-dGTP
also at physiological pH and to compare with the activ-
ity towards dGTP. The zfMTH1 enzyme displays consider-
able activity with O6-methyl-dGTP with a clear preference
over dGTP (Figure 6A) although the activity of zfMTH1
with O6-methyl-dGTP is not as high as for hMTH1. We
tested TH588 and TH1579, both potent inhibitors of hu-
man MTH1 and derived from the same chemical scaffold,
for inhibition of zfMTH1. Only TH588 was found to be a
potent inhibitor of zfMTH1 (IC50 = 12 nM) while no inhi-
bition could be observed with TH1579 even at 10 M (Sup-
plementary Figure S4A). Based on these results we decided
to use zebraish as a model and to use TH588 and TH1579
as tool compounds with TH1579 acting as a negative con-
trol not inhibiting zfMTH1. Microinjecting approximately
2 nl of a 150MO6-methyl-dGTP solution itself had no ef-
fect on embryo viability (95 ± 7.1% alive, n = 60), whereas
inhibition of MTH1 using 1.5 M TH588 in embryos in-
jected with O6-methyl-dGTP reduced viability to 16.7 ±
9.4% (n = 60) (Figure 6B and C). Exposure of injected em-
bryos with 1.5Mof theMTH1 inhibitor TH1579, not tar-
geting zfMTH1, had little effect on viability (88.3 ± 6.2%
alive, n = 60) (Figure 6B and C). This shows that active
zfMTH1 is needed to protect from the toxic effect of O6-
methyl-dGTP and shows the importance of MTH1 in re-
moving O6-methyl-dGTP from the nucleotide pool in an in
vivo model.
MTH1 protects against O6-methyl-dGTP being incorpo-
rated into DNA
To test if O6-methyl-dGTP is incorporated into DNA and
exerts its toxicity through induction of DNA damage we
extracted DNA from zebraish embryos microinjected with
O6-methyl-dGTP and treated with or without MTH1 in-
hibitor TH588, as well as from untreated control embryos.
Levels of O6-methyl-dG and N7-methyl-dG in DNA were
analysed using LC–MS/MS.Results show that embryosmi-
croinjected with O6-methyl-dGTP have considerably higher
levels of O6-methyl-dG inDNA compared to untreated em-
bryos (Figure 6D). Treatment with TH588 only causes a
slightly increased level of O6-methyl-dG in the DNA pos-
sibly due to incorporation of endogenously produced O6-
methyl-dGTP. We also determined the levels of N7-methyl-
dG in DNA as a control and could not observe any signii-
cant differences between treatment groups (Supplementary
Figure S5). The inding that the levels of N7-methyl-dG in
DNA is not affected byMTH1 inhibition is consistent with
the observation that N7-methyl-dGTP is not a MTH1 sub-
strate (Supplementary Figure S1B).
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Figure 5. Crystal structures of hMTH1 and zfMTH1 in complex with O6-
methyl-dGMP. (A) Electron density of O6-methyl-dGMP bound to hu-
man MTH1: 2Fo-Fc map at 2.0 . hMTH1 is shown in off-white and
O6-methyl-dGMP in green. Important binding residues and residues of
the hydrophobic pocket are shown as sticks and labelled. Hydrogen bond-
ing distances in Angstroms are shown. (B) Electron density of O6-methyl-
dGMPbound to zebraishMTH1: 2Fo-Fcmap at 2.0 . zfMTH1 is shown
in purple and O6-methyl-dGMP in cyan. Important binding residues and
residues of the hydrophobic pocket are shown as sticks and are labelled and
hydrogen bonding distances in Angstroms are indicated. (C) Comparison
of O6-methyl-dGMP and 8-oxo-dGMP bound to human MTH1. Human
MTH1 is shown in off-white for the O6-methyl-dGMP bound structure
and in pink for the 8-oxo-dGMP bound structure. O6-methyl-dGMP is
shown in green and 8-oxo-dGMP is shown in orange. Important binding
residues and residues of the hydrophobic pocket are shown as sticks and
labelled. The E52, E56 and E100 binding the magnesium critical for the
catalytic activity are also labelled and shown as sticks.
O6-methylguanine-DNA methyltransferase (MGMT) is
the main repair pathway for repair of O6-methyl-dG in
DNA as evidenced by the large impact of cellular MGMT
levels on toxicity of alkylating agents (2,42). MGMT re-
moves the methyl-group on O6-guanine when present in
DNA (43). We reasoned that inhibition of MGMT would
enhance the toxicity of O6-methyl-dGTP injected into fer-
tilized zebraish embryos only if O6-methyl-dGTP is incor-
porated into theDNA and therefore analysed the protective
role of activeMTH1 andMGMTonO6-methyl-dGTP tox-
icity using TH588 and the MGMT inhibitor Lomeguatrib
(44). Analysis of survival of zebraish embryos injected with
O6-methyl-dGTP and treated with the MTH1 inhibitor
TH588 and/or the MGMT inhibitor Lomeguatrib shows
that neither O6-methyl-dGTP nor Lomeguatrib treatment
are toxic on their own. However, inhibition of MGMT
causes a 1.3-fold sensitization to O6-methyl-dGTP in ab-
sence of TH588 (with active zfMTH1) and a 1.5-fold sensiti-
zation to O6-methyl-dGTP in presence of TH588 inhibiting
MTH1 compared to the effect of the combined individual
treatments 24% vs 18.4% (6.2% + 12.2%) dead embryos and
94.3% versus 62% (6.2% + 12.2% + 43.6%) dead embryos,
respectively, consistent with O6-methyl-dGTP being incor-
porated into the DNA (Figure 6E and F).
MTH1 deiciency increases apoptosis and decreases viability
in Temozolomide treated cells
Treatment of the glioblastoma cell line U251-MTH1
(MTH1 deicient) and the isogenic U251 cell line (MTH1
proicient) (Supplementary Figure S6) with Temozolomide
shows that the cells lacking MTH1 are more sensitive to
Temozolomide as assessed by viability assay using resazurin
(Figure 7A) with EC50 values 3.6-fold higher for theMTH1
proicient cell line (62±4 M) compared to the MTH1 de-
icient cell line (17±10 M). The difference in sensitivity to
Temozolomide between the two cell lines increases to 6.6-
fold whenMGMT is inhibited using 12.5 MLomeguatrib
(EC50 = 79±2 M for the MTH1 proicient cell line and
EC50 = 11±2 M for the MTH1 deicient cell line) (Figure
7A and B). Inhibition of MGMT using Lomeguatrib (12.5
M) also causes increased early apoptosis as measured by
Caspase 3/7 activity in the MTH1 deicient (U251-MTH1)
compared to the MTH1 proicient cell line (U251) (Figure
7C and D). This result is consistent with what would be ex-
pected ifMTH1 protects the cell by hydrolyzing O6-methyl-
dGTP and thereby preventing its incorporation into DNA.
Higher levels of O6-methyl-dG in the DNA through incor-
poration of O6-methyl-dGTP would make the cell more de-
pendent on functional MGMT for cell survival.
DISCUSSION
Activity of MTH1 with O6-methyl-GTP
MTH1 is here shown to eficiently catalyze the hydrolysis
of O6-methyl-dGTP but was also shown to display low ac-
tivity with O6-methyl-GTP (Figure 1B, Table 1). However,
since the concentration of GTP in the cell is approximately
100 times higher than the concentration of dGTP (45) the
concentration of O6-Methyl-GTP is likely to bemagnitudes
higher than O6-Methyl-dGTP and the activity of MTH1
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Figure 6. Active zfMTH1 is crucial for zebraish embryo survival after O6-methyl-dGTP exposure. (A) The zfMTH1 enzyme catalyzes the hydrolysis of
O6-methyl-dGTP eficiently. 100 M dGTP or O6-methyl-dGTP was incubated with 5 nM zfMTH1 or hMTH1 for 20 min. Formed PPi was converted to
Pi by using an excess of E. coli PPase and Pi was detected using malachite green reagent. Statistical signiicance was determined using multiple comparison
and Two way Anova using the GraphPad Prism 6.0 software. (B) O6-methyl-dGTP (150 M) was injected into fertilized zebra ish eggs followed by
treatment with DMSO, TH588 (1.5 M) or TH1579 (1.5 M). Picture shows zebraish embryos from a representative experiment. (C) Quantiication of
zebraish survival. Inhibition of zfMTH1 in combination with microinjecting O6-methyl-dGTP in zebraish is clearly toxic to ish embryos. Graph shows
average and standard deviations from three independent experiments. (D) Levels of O6-methyl-dG per million dN in DNA as measured by LC–MS/MS.
DNA was extracted from DMSO or TH588 treated zebraish embryos, zebraish embryos microinjected with O6-methyl-dGTP or from O6-methyl-dGTP
microinjected and TH588 treated zebraish embryos. Graph showsmean and SEM from two independent experiments. Statistic signiicance in C andDwas
tested using multiple comparisons and One way Anova, P≤ 0.05 are indicated by *. (E) Percentage dead embryos after microinjection of O6-methyl-dGTP
and inhibition of zfMTH1 and MGMT through treatment with TH588 (1.5 M) and Lomeguatrib (10 M), alone and in combination, compared to
untreated zebraish embryos. Graph shows average ± SD from three independent experiments. (F) Co-treatment of O6-methyl-dGTP injected zebraish
eggs with TH588 and Lomeguatrib signiicantly decreases the survival of zebraish embryos compared to the effects of the combined individual treatments.
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Figure 7. MTH1 deiciency sensitizes cells to Temozolomide. Cell viability of U251 (MTH1 proicient) and U251-MTH1 (MTH1 deicient) was measured
using resazurin after 96 h of treatment with Temozolomide and Lomeguatrib. (A) EC50 values for Temozolomide was determined to 62±4 M for MTH1
proicient and 17±4 M forMTH1 deicient cells with activeMGMT, respectively. (B) EC50 values for Temozolomide were 79±2 M forMTH1 proicient
and 11±2 M for MTH1 deicient cells whenMGMT is inhibited with 12.5 MLomeguatrib. MTH1 deiciency causes a 3.6-fold sensitization with active
MGMT, and increases to 6.6-fold uponMGMT inhibition. Figures show representative experiments out of two independent experiments per treatmentwith
data points in duplicate. Caspase 3/7 activity, detecting early apoptosis, was assayed using U251 andU251-MTH1 cells after treatment with Temozolomide
ranging from 0 to 100 M for 48 h (C) or with both Temozolomide and Lomeguatrib (12.5 M) (D). MTH1 deicient cells show increased caspase 3/7
activity at 50 and 100 M Temozolomide when MGMT is inhibited with 12.5 M Lomeguatrib. Shown are representative experiments out of three
independent experiments with data points in duplicate. Data are presented as average ± SEM. Statistical signiicant differences were determined using
multiple comparison and Two way Anova in GraphPad Prism 6.0, P ≤ 0.01 is indicated by**.
may also be relevant and important to prevent incorpora-
tion into RNA, which has been shown to change the idelity
and to decrease the translation rate (15). MTH1 has been
reported to display an approximately 20-fold preference for
8-oxo-dGTP over 8-oxo-GTP (46) mostly due to a higher
Km value for the ribonucleotide substrate. For O6-methyl-
dGTP and O6-methyl-GTP there is a large difference be-
tween both the Km and the kcat values (Table 1) indicating
that both afinity and catalytic activity is affected by reduc-
ing the 2′ carbon as in the O6-methylated guanine ribonu-
cleotide. Analysis of the role of MTH1 on removal of O6-
methyl-GTP from the nucleotide pool will be the subject of
future research.
Activity of NUDT17 and NUDT18 with O6-methyl-dGTP
NUDT17 and NUDT18 were the only two enzymes apart
fromMTH1 among the tested NUDIX hydrolases that dis-
played O6-methyl-dGTP activity. These enzymes have pre-
viously been shown to display activity with oxidized nu-
cleotides like MTH1, but with considerably lower activity
(41). This study further supports the notion that NUDT17
and NUDT18 share some features with MTH1. NUDT17
also seems to display some preference for methylated nu-
cleotides over nonmethylated nucleotides similar toMTH1,
as observed when assessing activity with a larger panel
of methylated and nonmethylated nucleotides (Figure 3B).
However, the activity of NUDT17 and NUDT18 is ∼80-
fold lower with O6-methyl-dGTP compared to MTH1 and
is not likely to make any major contribution to the hydrol-
ysis of O6-methyl-dGTP in MTH1 proicient cells.
Analysis of MTH1 structures with bound O6-methyl-dGMP
We sought to provide an explanation to the high activity of
MTH1 with O6-methyl-dGTP by analysing the structures
of both human and zebraish MTH1 in complex with O6-
methyl-dGMP. O6-methyl-dGMP was found to be clearly
bound to both human and zebraish MTH1 as seen from
the electron density in Figure 5A and B. Given the shift of
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1.1 A˚ in position of the base of O6-methyl-guanine com-
pared to when 8-oxo-dGMP is bound to MTH1 (see Fig-
ure 5C), it is likely that the methylation of O6 is strength-
ening the binding of the base to the hydrophobic pocket.
The residuesGlu52, Glu56 andGlu100 are expected to bind
the magnesium needed for hydrolysis, and as shown in Fig-
ure 5C their positions are identical. It is clear that the hy-
drolysis of the phosphates is performed in the same manner
for 8-oxo-dGTP and O6-methyl-dGTP and the kinetics of
the MTH1 activity is determined by the binding of the sub-
strate to the active site. The hydrophobic pocket has previ-
ously been explored for drug development as described for
TH287 and TH588 (22). The structures are highly similar
as shown by RMSD values, and the main difference is the
position of the methylated base. The structural analysis re-
veals differences in the hydrogen bonding networkwhen hu-
man MTH1 binds 8-oxo-dGMP and O6-methyl-dGMP as
shown inFigure 5C. Interestingly, when bindingO6-methyl-
dGMP Asp119 needs to be protonated but when binding
8-oxo-dGMP it seems as if either Asp119 or Asp120 could
be protonated (17) and in the MTH1 structure with 8-oxo-
dGTP bound Asp119 is protonated (47). The few differ-
ences in the binding pocket, Y7L and P118A going from
human to zebraish, do not seem to inluence the binding
of O6-methyl-dGMP as shown in Supplementary Figure
S4B. The observed binding of calcium ions in zfMTH1 is
likely due to the presence of calcium in the successful crys-
tallization conditions. Calcium ions were found to bind in
the crystal contact with another proteinmonomer, however,
the metal ions also bind in to the NUDIX-box motif as
expected (Supplementary Figure S7) as previously shown
for the related protein NUDT15 (41). The binding mode
is however different between zfMTH1 and NUDT15 (Sup-
plementary Figure S8) and based on the available data the
position of the magnesium ions in zfMTH1 in solution re-
mains unknown. Another explanation for calcium ions be-
ing found in the zfMTH1 structure could be that zfMTH1
utilizes Ca2+ instead of Mg2+. However, when testing the
activity of zfMTH1 upon replacing Mg2+ with Ca2+ no ac-
tivity was observed disproving this theory (Supplementary
Figure S9).
Physiological relevance of the MTH1 activity with O6-
methyl-dGTP
We here present O6-methyl-dGTP as a novel and excel-
lent substrate for MTH1. MTH1 displays a catalytic ef-
iciency with O6-methyl-dGTP that is in the same range
as for its known substrate 8-oxo-dGTP, implying that hy-
drolysis of O6-methyl-dGTP indeed is an important func-
tion of MTH1. This activity was found to be conserved in
MTH1 homologues from several different species, ranging
from organisms as distantly related as plants and zebraish
to humans, strongly indicating that this activity is bene-
icial to the cell. O6-methyl-G adducts are removed from
DNA by MGMT in a suicide reaction where the methyl
group is transferred to a cysteine in the active site of the
enzyme (14). Mammalian cells lacking MGMT have been
shown to be very sensitive to methylating agents (48), and
mice lacking MGMT are hypersensitive to agents that pro-
duce O6-methyl-G (49,50). If not removed O6-methyl-G in
DNA leads to mutations, DNA strand breaks and collapse
of replication forks (5). Removal of O6-methyl-dGTP from
the nucleotide pool would potentially be of high importance
to prevent incorporation into DNA in cells where the ca-
pacity of MGMT is low and when the cell is exposed to
methylating substances resulting in levels ofO6-methyl-G in
the DNA high enough to override the capacity of MGMT.
Some tumors lack MGMT due to epigenetic silencing of
the MGMT gene and consequently such tumors are more
sensitive to methylating agents and are reported to respond
better to treatment with alkylating drugs (51). Inhibition
of MTH1 in such a background may sensitize the tumors
even more to methylating agents and further improve the
response. We show that zebraish embryos are dependent
onMTH1 activity for survival when exposed to O6-methyl-
dGTP. We demonstrate that O6-methyl-dGTP is incorpo-
rated into DNA and that the toxicity of O6-methyl-dGTP
is enhanced when MGMT is inhibited. Together, these re-
sults strongly suggest that MTH1 catalyzed hydrolysis of
O6-methyl-dGTP to O6-methyl-dGMP renders the methy-
lated nucleotide harmless by preventing its incorporation
into DNA.
Temozolomide is an alkylating drug known to exert its
toxicity through production of O6-methyl-dG (1). Temo-
zolomide is used for treatment of glioblastoma multiforme
since it due to its small size and lipophilicity is among the
few drugs that can pass the blood brain barrier and can
therefore be used to treat cancer in the central nervous sys-
tem (33). Temozolomide is a prodrug that needs to un-
dergo hydrolysis to form the active metabolite 3-methyl-
(triazen-1-yl)imidazole-4-carboxamide that in turn breaks
down to produce the reactivemethyldiazonium ionmetabo-
lite (52,53). Although no study yet has reported the for-
mation of O6-methyl-dGTP in cells upon Temozolomide
treatment, O6-methyl-dGTP was shown to be produced in
cells treated with N-methyl-N-nitrosourea that decomposes
to the same reactive methyldiazonium ion metabolite as
Temozolomide (3). This strongly suggests that O6-methyl-
dGTP also is formed in cells upon Temozolomide treat-
ment. This notion is further strengthened by the fact that
glioblastoma cells deicient inMTH1were shown to display
a higher sensitivity to Temozolomide compared to MTH1
proicient cells, most likely through different abilities to
remove formed O6-methyl-dGTP. Since Temozolomide is
more effective in treating cancers with lowMGMT levels we
tested the effect of co-treatment with the MGMT inhibitor
Lomeguatrib (Figure 7B and D). Inhibition of MGMT
was found to increase the observed difference in Temozolo-
mide sensitivity betweenMTH1 deicient andMTH1 proi-
cient cells clearly supporting a role of MTH1 in protecting
against the toxic effects of O6-methyl-dGTP, formed upon
methylation of dGTP, also in human cells.MTH1 inhibitors
could potentially be used to potentiate Temozolomide and
other alkylating drugs, acting through O6-methylation of
guanine. The shift in sensitivity to Temozolomide between
the MTH1 proicient and the MTH1 deicient cells (Figure
7A and B) can be ascribed to the fraction of Temozolomide
toxicity that is exerted through methylation of dGTP in the
free nucleotide pool producing O6-methyl-dGTP. Our re-
sult also shows that eukaryotic DNA polymerases can in-
corporate O6-methyl-dGTP into the growing DNA chain
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during replication as evidenced by the results of our analy-
sis of zebraish DNA (Figure 6D) showing increased levels
of O6-methyl-dG after microinjection of O6-methyl-dGTP
togetherwith the experimentswith human cells demonstrat-
ing thatMTH1 deiciency increases the sensitivity to Temo-
zolomide treatment (Figure 7). This has to our knowledge
previously only been shown for T4 bacteriophage DNA
polymerase (54,55).
We observed early apoptosis (Figure 7C andD) after 48 h
of Temozolomide treatment consistent with published data
describing that the Temozolomide toxicity appears at the
second round of replication after Temozolomide exposure
due to futile mismatch repair that induces apoptosis (56).
The major endogenous methylator SAMwas reported to
function as a weak alkylating substance and was found to
produce methylated nucleotides in the DNA in the form
of N7-methylguanine and N3-methyladenine but also O6-
methylguanine (2) indicating that there also may be a need
to remove O6-methyl-dGTP under normal cellular condi-
tions. The evolutionarily conserved MTH1 activity with
O6-methyl-dGTP presented here, as well as the presence of
MGMT enzymes in both prokaryotes and eukaryotes, to-
gether removing O6-methylated guanines from the DNA
and the free nucleotide pool clearly marks the importance
of protecting the cell against alkylating species producing
O6-methyl-dG.
In conclusion, this study reveals a novel function of
MTH1 as constituting another line of defence against the
cytotoxic and mutagenic O6-methylation of guanine by ef-
iciently catalysing the hydrolysis of O6-methyl-dGTP and
thereby preventing its incorporation into DNA. MTH1
emerges as a multifunctional enzyme important for sanitiz-
ing the cell from damaged nucleotides.
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